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Abstract
Background: Although pre-puberty asthma is more prevalent in males, after puberty through middle-age, asthma
is more prevalent in females. The surge of sex hormones with puberty might explain this gender switch.
Methods: To examine the effects of sex hormones on lung function and symptoms with puberty, Tanner stage was
assessed in 187 children 6–18 years of age (59% severe) enrolled in the NIH/NHLBI Severe Asthma Research Program
(SARP). The effects of circulating sex hormones (n = 68; testosterone, dehydroepiandrosterone sulfate (DHEA-S),
estrogen, and progesterone) on lung function and 4 week symptom control (ACQ6) in cross-section were tested
by linear regression.
Results: From pre−/early to late puberty, lung function did not change significantly but ACQ6 scores improved
in males with severe asthma. By contrast females had lower post-BD FEV1% and FVC% and worse ACQ6 scores
with late puberty assessed by breast development. In males log DHEA-S levels, which increased by Tanner stage,
associated positively with pre- and post-BD FEV1%, pre-BD FVC %, and negatively (improved) with ACQ6. Patients
treated with high-dose inhaled corticosteroids had similar levels of circulating DHEA-S. In females, estradiol levels
increased by Tanner stage, and associated negatively with pre-BD FEV1% and FVC %.
Conclusions: These results support beneficial effects of androgens on lung function and symptom control and
weak deleterious effects of estradiol on lung function in children with asthma. Longitudinal data are necessary to
confirm these cross-sectional findings and to further elucidate hormonal mechanisms informing sex differences in
asthma features with puberty.
Trial registration: ClinicalTrials.gov registration number: NCT01748175.
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Background
The prevalence of current asthma in the U.S. is higher
in children than in adults, and from pre-school to age
14 years is greater in boys than it is in girls [1]. Both
asthma severity and hospitalizations start to decrease in
late childhood and remain relatively low into young adult-
hood [2, 3]. After age 18 years, in young men, current
asthma prevalence is lower than in childhood; in young
women although lower than in childhood, current asthma
prevalence is higher than it is in young men, and remains
higher in women through middle-age [1]. Surges in en-
dogenous sex hormones across adolescence could affect
the “gender switch” in asthma status [2]. For example,
DHEA-S, a circulating androgen that increases with pu-
berty, inhibits human airway smooth muscle and airway
fibroblast proliferation [4, 5] and may influence airway
epithelial-to-mesenchymal transition [6]. Testosterone pro-
motes airway smooth muscle relaxation [7]. In women
both with and without asthma, FEV1% peaks at the end of
the luteal phase to the beginning of menstruation, and then
decreases when circulating estrogen and progesterone de-
crease [8]. Accordingly, the fall in circulating estrogen and
progesterone from the luteal to the follicular phase of the
menstrual cycle is accompanied by a reduction in lympho-
cyte β2 adrenoceptor density [9] and increased bronchial
responsiveness in women with asthma [10]. Recent studies
of dysanapsis (differential growth of airway caliber and lung
volume) in healthy subjects suggest that, by adulthood,
women develop more small airways resistance than do
men [11]. Thus these studies support interdependent ef-
fects of sex and endogenous sex hormones on lung growth,
and airways responsiveness that likely inform asthma status
from puberty to middle-age.
Puberty is a dynamic process regulated by hormonal
signals from the central nervous system that results in
sexual maturation. Assessment of the stage of pubertal
maturation is different in boys than girls [12]. In boys,
androgen production gradually increases both from testes
producing testosterone and the adrenal glands producing
weaker androgens—ultimately leading to pubarche. Girls
experience increases in the production of estrogen from
the ovaries (driving thelarche and ultimately menarche)
and androgens such as androstenedione and DHEA-S
from the adrenal glands (driving pubarche in girls) [13]. In
children studies of pubertal maturation and asthma status
furthermore may be affected by corticosteroid treatment
[14]. The primary purpose of the current studies was to
do a cross-sectional analysis of the effects of pubertal mat-
uration and sex hormone levels on asthma features in a
sample of children enrolled in SARP. We found important
differences in phenotypic features according to sex and
pubertal stage. In boys higher DHEA-S levels positively
associated with greater FEV1% predicted and improved
4 week symptoms, whereas in girls, breast development,
signifying estradiol effects, weakly associated with lower
lung function.
Methods
Severe asthma research program
Details of the SARP III network, recruitment targets,
enrollment and characterization procedures, and the
longitudinal protocol have been previously published
[15, 16]. Active tobacco smokers were excluded. Partici-
pants maintained medications for asthma as prescribed
by their care provider. Study procedures were approved
by the IRB at each institution and an independent Data
Safety Monitoring Board (Additional file 1: Figure S1).
All subjects provided written informed consent and/or
assent. The study is listed on ClinicalTrials.gov.
Criteria for enrollment
Enrollees met criteria for current asthma based on re-
sponsiveness to β-agonist (≥12% increase in FEV1 from
baseline post-albuterol) and/or positive methacholine
bronchoprovocation. Severe asthma was defined accord-
ing to the ERS/ATS consensus definition [17]. Children
whose asthma required treatment with high-dose inhaled
corticosteroids (≥440 mcg of fluticasone equivalents per
day for children 6–11 years of age; ≥880 mcg fluticasone
equivalents per day ≥12 years of age) plus a second con-
troller and/or systemic corticosteroids to maintain asthma
control or which was uncontrolled despite these medica-
tions were assigned to the severe sub-group. Medications
at this level were required for at least 6 of the previous
12 months and the 3 months prior to enrollment for par-
ticipants to qualify for the severe sub-group. Those who
did not meet criteria for severe asthma were assigned to
the non-severe sub-group.
Characterization
Characterization procedures extended from the SARP I
and II protocols [18–20] for SARP III included detailed
history and physical examination, vital signs, height, weight,
characterization questionnaires, assessment of four-week
symptom control (asthma control questionnaire; ACQ6
[21]), and spirometry with maximal β-agonist reversibility
testing (dose escalation protocol at 180 mcg albuterol incre-
ments up to 720 mcg).
Blood was drawn during the visit but not with systematic
timing related to the timing of the spirometry. Pubertal
stage was determined by study coordinators and investiga-
tors certified a priori to enrollment by a pediatric endocrin-
ologist (MDD) with the method of Marshall and Tanner
[12]. To identify central (CNS) puberty, Tanner stage for
males was based on pubic hair and for females breast devel-
opment. Females were also separated into pre−/early adre-
narche and mid−/late adrenarche based on Tanner stages
of pubic hair.
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Spirometry, maximum bronchodilator challenge and
methacholine challenge were performed by study coordi-
nators certified after standard training and completion
of an examination administered by the SARP III Data
Coordinating Center on ATS-compatible equipment. Qual-
ity analysis of lung function tests and validation of results
was accomplished by inspection of randomly sampled flow
volume plots by a central over-reader. Population reference
standards adjusted for age, height, and sex were from the
Global Lung Initiative (GLI) [22].
Sex hormone assays
Sex hormone and SHBG levels were analyzed at the
University of Virginia Center for Research in the
Reproduction Ligand Core Laboratory. Estradiol levels
were assessed with Calbiotech ELISA and all other metab-
olites were assessed using the Siemens Immulite 2000.
Free testosterone was calculated from total testosterone
and SHBG as previously described [23]. The lower limit of
detection for assays were: testosterone 20 ng/dL; DHEAS
15 μg/dL; progesterone 0.20 ng/mL; and SHBG 10 nmol/
L. For the purpose of mathematical analyses, individuals
with measurements below the limit of detection were
counted as having a value just below the lower limit of
detection. Intra−/inter-assay coefficients of variation (CVs,
%) were as follows: estradiol 6.3/8.1, testosterone 4.4/7.5,
DHEAS 5.4/6.5, progesterone 4.4/7.8, and SHBG 2.7/5.2.
Data analysis
The analysis was restricted to enrollees with complete
data sets with regards to Tanner stage and lung function.
Because of natural variation in recruitment, mid-Tanner
stages were relatively under-represented (Table 1). To
examine the effects of pubertal maturation, partici-
pants were assigned to sub-groups including those
with pre−/early puberty (Tanner 1–2) and mid-late
puberty (Tanner 3–5).
Categorical data are presented as count and percentage,
and continuous data as means ± standard deviations. Com-
parisons of differences by pubertal stage between males and
females (both adrenarche and breast development) was per-
formed by testing the stage by sex interaction term in a
simple regression model. PC20 was evaluated on a log base
2 scale, with two zero values replaced by 0.016, or half of
the minimum non-zero value. Univariable linear regression
was used to evaluate relationships between measures of
lung function or ACQ6 and individual 5-level Tanner stage.
Multivariable linear regression tested associations of clinical
outcomes (lung function and ACQ6) with sex hormone
levels (for males, testosterone and DHEA-S; for females,
estradiol, progesterone, free testosterone and DHEAS) as
co-variates. With a backward selection method, hormones
that were not significantly associated with the outcome
were removed in steps and only significant associations
were reported. These analyses were then further strati-
fied based on BMI ≥85th percentile and < 85th percent-




The sample included 116 males and 71 females (Table 1).
There were no significant differences between males and fe-
males with regard to age, racial/ ethnic background, asthma
severity, or corticosteroid treatment. There were 110 severe
and 77 non-severe participants in the analytic cohort. Of
these, 74 severe- and 30 non-severe participants had an
ACQ < 1.0 as an estimate of poor control (67% and 39%, re-
spectively) [24]. Overall the sample was enriched in African
Americans and severe asthma, with a high proportion
with atopic sensitization. Among males, 84 (63%) were
in pre−/early puberty and 32 (28%) in mid−/late puberty
by Tanner stages of pubic hair development. Among fe-
males, 32 (45%) were in pre−/early puberty and 39 (56%)
in mid−/late puberty by Tanner stages of breast develop-
ment. 37 females (52%) were in pre−/early- and 34 (47%)
in mid−/late adrenarche by Tanner stages of pubic hair.
Adolescent females discordant for breast and pubic hair
stages of development included 6 wherein pubic hair
stage exceeded breast stage, and 1 wherein breast stage
exceeded pubic hair (Additional file 1: Table S1).
Differences in sex hormones with puberty
68 children in the sample had circulating sex hormones
measured (45 males, 23 females). From pre−/early to mid
−/late puberty, testosterone increased in males, and estra-
diol increased in females (Additional file 1: Figure S2A and
B). Likewise with puberty DHEA-S increased in males and
DHEA-S, progesterone, and free testosterone increased in
females (results not shown).
Differences in lung function with puberty
For males, there was a tendency for lung function and
the maximum bronchodilator response to improve with
pubertal maturation, but these differences were not statisti-
cally significant (Table 2). By contrast in females, both the
post-bronchodilator FEV1% and FVC % were significantly
lower (by 8.9% and 9.1% respectively, p = 0.01 each) from
pre−/early to mid−/late puberty as determined by breast
development. In an analysis limited to severe females alone
(n = 44), the lower FEV1 (%) from early to late puberty
remained significant. Similarly, the differences by pubertal
maturation remained when participants were stratified by
overweight/obesity status (Additional file 1: Table S2-A-1
and S2-A-2). These differences by Tanner stage are attribut-
able to breast and not pubic hair development, supporting
a likely estradiol effect.
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Differences in ACQ6 with puberty
With regards to four week symptom control (Table 3),
with males (n = 116) the ACQ6 was not significantly
different from pre−/early to mid−/late puberty, whereas
in females (n = 71) the ACQ6 was higher (worse) with
puberty assessed by breast bud (p < 0.05) and by pubic
hair development (p < 0.05). In males with severe but
not non-severe asthma, the ACQ6 was lower (im-
proved) with pubertal maturation, whereas the ACQ6
was higher with pubertal stage in females with both se-
vere (n = 44) and non-severe (n = 37) asthma (p < 0.05
for both). Again, the differences by pubertal maturation
remained when participants were stratified by over-
weight/obesity status (Additional file 1: Table S2-B-1
and S2-B-2).
Multi-variable linear regression of lung function and
ACQ6 with sex hormones
Males
For males in the sample 6–18 years of age, lung function
associated positively with log DHEA-S values (Table 4).
The pre-bronchodilator FEV1% (β = 8.05; p = 0.01), post-BD
FEV1% (β = 8.82, p = 0.008), and pre-BD FVC % (β = 8.33,
p = 0.01) had strongly positive β coefficients. The ACQ6
had a negative β coefficient with higher log DHEA-S values
(β = − 0.59, p = 0.007), indicating 4 week symptom improve-
ment. These associations were driven largely by participant
who were overweight/obese (Additional file 1: Table S3-A-1
and S3-A-2). The final model predicting ACQ6 included
negative β coefficients for both log DHEA-S and testos-
terone, as well as the interaction of log DHEA-S with






Age, years, mean (± sd) 11.3 (± 2.7) 11.8 (± 3.1) 0.21
Age of asthma diagnosis 3.1 (± 2.7) 3.1 (± 2.7) 0.90
Years since onset of asthma symptoms (asthma duration) 9.0 (± 3.2) 9.4(± 3.5) 0.50
BMI percentile 76.9 (± 26.5) 73.5 (± 27.1) 0.40
Race/ethnicity, n (%)
White non-Hispanic 28 (24) 26 (37) 0.26
African American non-Hispanic 51 (44) 26 (37)
Hispanic 17 (15) 11 (15)
Other 20 (17) 8 (11)
Asthma severity, n (%)
Severe 66 (57) 44 (62) 0.49
Not severe 50 (43) 27 (38)
Systemic Corticosteroid Treatment (current) 11 (9) 5 (7) 0.56
Systemic Corticosteroid Treatment (past 3 mos) 7 (6) 3 (4) 0.59
High-Dose Inhaled Corticosteroids 82 (71) 50 (70) 0.97
Low-Medium-Dose Inhaled Corticosteroids 23 (20) 14 (20) 0.99
Montelukast (during last 12 months) n(%) 71 (60) 54 (76) 0.03
Long-acting beta agonist 86 (74) 49 (69) 0.45
Atopic sensitization
At Least One Positive Specific IgE (of 15 tests) 106 (93) 64 (91) 0.70
Number of Positive Specific IgEs (of 15 tests). Mean (± sd) 7.0 (4.3) 7.0 (4.9) 0.95
History of atopic dermatitis. n(%) 74 (64) 44 (62) 0.80
Tanner stage, n (%) Males Females
Pubic hair Breast development Pubic hair
I 67 (58) 14 (20) 24 (34)
II 17 (15) 18 (25) 13 (18)
III 8 (7) 16 (23) 8 (11)
IV 7 (6) 9 (13) 13 (18)
V 17 (15) 14 (20) 13 (18)
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testosterone, an association not present when the co-
hort was stratified by overweight/obesity status. Circu-
lating DHEA-S levels in males did not vary significantly
when compared according to treatment with high-dose
versus medium-dose inhaled corticosteroids (Additional
file 1: Figure S3).
Females
For females 6–18 years of age, androgens associated posi-
tively, but estrogens negatively with lung function (Table 5).
Free testosterone had a positive association with post-BD
FEV1% (β = 3.99, p = 0.04). In contrast, estradiol had nega-
tive β coefficients for pre-BD FEV1% (β = − 0.47, p = 0.03),
post-BD FEV1% (β = − 0.62, p = 0.0009), pre-BD FVC %
(β = − 0.36, p = 0.04), and post-BD FVC % (β = − 0.33,
p = 0.03). These associations were not significant in
either group when stratified by overweight/obesity status
(Additional file 1: Table S3-B-1 and S3-B-2). For the
ACQ6, only log DHEA-S had a significant association, it
varied positively (β = 0.49, p = 0.05) and the correlation
was relatively weak. ACQ6 was not associated with age
(Additional file 1: Table S4).
Discussion
In children enriched in severe asthma enrolled in the NIH/
NHLBI SARP III study (n = 187), there were important dif-
ferences in lung function and four-week symptom control
between males and females with pubertal maturation.
In males, lung function was not different and symptom
control improved when comparing those in early vs.
late puberty, whereas in females lung function and symp-
tom control were worse. Circulating sex hormones changed
with puberty; in males greater androgen levels associated
with better lung function and ACQ6, while in females
greater circulating estrogens had a weak but significant
negative association with lung function. These results
support the general hypothesis that with pubertal matur-
ation asthma severity is likely to improve in males but
worsen in females [2]. Furthermore our data suggest a
beneficial effect of endogenous androgens on lung func-
tion growth and ACQ6 in males in later puberty; and that
endogenous estrogens may have weak deleterious effects
on lung function growth in girls.
A beneficial effect of androgens is suggested by the pres-
ence of fewer asthma symptoms in late Tanner stage males
with severe asthma. In females the presence of more
asthma symptoms in late adolescence either reinforces
the benefit of androgens (given an absence of signifi-
cant androgens in females) or supports a negative role
for estradiol. These integrated, Tanner-stage-based mea-
surements of the effect of sex hormones over time are com-
plemented by the association between DHEA-S and fewer
asthma symptoms (lower ACQ6) and higher pre- and post-
albuterol FEV1% observed in boys. Given that GLI-based
normal ranges of lung function are age-specific these mat-
urational and hormone-associated measures appear to be
present beyond the expected changes in lung function
based on age alone. Furthermore, we did not note associa-
tions between ACQ6 and age in either boys or girls. Note
that it is unlikely that the level of corticosteroid therapy
Table 5 Multi-variable regression analysis of lung function and ACQ6 by sex hormone levels in females 6–18 years with asthma
Outcome variable Covariate remaining in the model* Beta coefficient Covariate p value R squared P value of the model
Pre-BD FEV1 (%) Estradiol −0.457 0.028 0.209 0.028
Post-BD FEV1 (%) Estradiol −0.454 0.005 0.320 0.005
Pre-BD FVC (%) Estradiol −0.351 0.025 0.217 0.025
Post-BD FVC (%) Estradiol −0.322 0.015 0.249 0.015
ACQ6 log (DHEA-S) 0.006 0.048 0.173 0.048
*Results reflect final results of a model that started with log (DHEA-S), estradiol, progesterone, and free testosterone as covariates. Covariates that were not
significantly associated with the outcome in this model were then removed by backward selection and model was re-run with remaining variables
Table 4 Linear regression analysis of lung function and ACQ6 by sex hormone levels in males 6–18 years with asthma
Outcome variable Covariate remaining in the model* Beta coefficient Covariate p value R squared P value of the model
Pre-BD FEV1 (%) Log (DHEA-S) 9.285 0.011 0.168 0.011
Post-BD FEV1 (%) Log (DHEA-S) 9.527 0.006 0.160 0.006
Pre-BD FVC (%) log (DHEA-S) 9.121 0.007 0.157 0.007
ACQ6 Log (DHEA-S) −0.008 0.019 0.214 0.018
Testosterone −0.005 0.031
log (DHEA-S) *Testosterone # 0.003 0.05
*Results reflect final results of a model that started with testosterone and DHEA-S. Covariates that were not significantly associated with the outcome in this model
were then removed by backward selection and model was re-run with remaining variables. # A log (DHEA-S) * testosterone interaction was found and included in
the final model
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caused the male/female discordance we observed because
the males and females did not differ with regard to oral
or inhaled corticosteroid dosing (Table 1). Furthermore
treatment with high-dose corticosteroids did not suppress
DHEA-S levels in males. Although the testosterone in-
crease is quantitatively orders of magnitude greater than
that of DHEA-S with puberty [25, 26], DHEA-S levels in
our analysis were more strongly associated with better
lung function and improved ACQ6 than was testosterone.
Of note, androgen receptors are expressed in bronchial
smooth muscle tissue, and testosterone relaxes contracted
airway smooth muscle, suggesting a beneficial effect of an-
drogens on airway smooth muscle tone [7]. Additionally,
DHEA-S inhibits human airway smooth muscle and air-
way fibroblast proliferation [5], and may influence airway
epithelial-to-mesenchymal transition [6], suggesting that
androgens may prevent adverse airway remodeling seen in
severe asthma. Together, these affects could be associated
with the lower asthma symptom scores we observed in
association with increased DHEA-S and with late adoles-
cence. Indeed a trial of androgen administration provided
early data regarding safety and improved ACQ [27]. We
noted associations between DHEA-S and lung function
that were present in overweight/obese but not normal
weight. This differential effect by weight status, which was
seen only in boys, is of unclear significance and requires
further investigation.
In females, subtle but significant discordance between
loss of lung function observed in association with late
puberty assessed by breast staging relative to pubic hair
staging suggests that estrogen, which drives breast develop-
ment, may be the main factor affecting lung function. Only
females have a surge of estrogen or progesterone during
puberty, and breast development is exclusively associated
with this surge [28]. In our study the number of females
with discordant pubertal examinations was small, whereas
adrenal androgen effects confounded all assessments. We
also cannot exclude an adverse effect of progesterone. For
example, the effects of pregnancy on lung function may
be either both estrogen and progesterone-dependent,
and both hormones have been hypothesized to play
roles in the worsening of lung function [2].
These results likewise support disparate changes in
lung growth between males and females with puberty
that bear on the remarkable decline in hospitalizations
and asthma severity seen in young adults [3]. Asthma
prevalence appears to decline more in males than it does
in females by the second decade of life [1], a result
which might be explained by disparate trends in airway
growth due to sex hormones. Young adult females ex-
hibit a “dysanaptic” pattern of airway growth which sup-
ports a pattern of anatomically “fixed” airflow limitation
[11]. With regards to airway hyperreactivity, we found
that the level of methacholine responsiveness actually fell
in both males and females with Tanner stage, a finding dif-
fers from the results of Tantisera et al. [29] wherein females
had increased methacholine responsiveness. The difference
between the two studies may be due to sample differences,
wherein the SARP III cohort is relatively enriched with
African Americans and children with severe asthma.
It should also be noted that other hormonal changes dur-
ing puberty could also affect lung function, including an in-
crease in the degree of insulin resistance [30]—which itself
is associated with increased risk of asthma in adults [31] and
adolescent girls [32]—and elevations in stress hormones,
including cortisol [33]—with such stress systems further
associated with asthma risk [34]. While temporally related
(i.e., during puberty), the processes of insulin resistance and
stress response go beyond sex hormone regulation alone
[30, 33]. Unfortunately, the timing of our blood collection
was not specifically in the early morning (thus not as helpful
to assess cortisol regulation) or with fasting status (for asses-
sing insulin resistance), and thus we were not able to assess
how these processes may have interacted with changes in
sex hormones. Nevertheless, because we were able to assess
relationships between measured levels of sex steroids and
outcomes important to asthma severity, our findings suggest
a direct role for sex steroids themselves.
This cross-sectional analysis of the effects of puberty
on asthma features is exploratory and intended primarily
to identify specific hypotheses to be tested with longitu-
dinal measurements. We would point out that the ver-
acity of the results is limited by the cross-sectional
analytic approach, and the relative paucity of children
who were in the mid-Tanner stages (III/IV) at the time
of enrollment and our lack of knowledge for most fe-
male participants of whether central puberty or adre-
narche began first. We lacked data on some participant
characteristics, including depression status—which could
affect stress response [34]—and the fraction of excreted
nitrosoxide (FeNO)—which would have permitted as-
sessment of the relationship between hormone levels
with activity of Th2-high airway inflammation.
Conclusions
These results impact understanding of the differences in
asthma features with pubertal maturation and the potential
for new treatment. The androgen surge with puberty is
likely to confer protective effects on lung growth in both
males and females whereas estrogens may well have dele-
terious effects in females extending into adult development.
A trial of weak androgen therapy in adolescent children
with low androgen levels and poorly-controlled asthma
could be considered to improve lung function. These data
may help to explain the gender switch observed in asthma
incidence during adolescence and likewise inform lung
growth and asthma severity with subsequent maturation
into adulthood.
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Additional file 1: Sex Hormones & Asthma. Type of data: Tables and
Figures. (DOCX 468 kb)
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